Undisclosed Chi3l1 inhibitor / Ocean Biomedical - LARVOL DELTA

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China (GlobeNewswire) - "Ocean Biomedical, Inc...today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells....The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells....The grant of this patent follows Ocean Biomedical’s continued success in securing intellectual property protection across key markets, including the United States and Europe."

Patent • Solid Tumor

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses (GlobeNewswire) - "Ocean Biomedical...announced today that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body’s natural immune responses to lung cancers....'The ability of CHI3L1 to simultaneously inhibit innate immune responses, stimulate ICPs, inhibit T cell costimulation, and regulate a number of other oncogenic and inflammation pathways suggests that CHI3L1-targeted therapeutics are promising interventions in cancer'....Dr. Elias’ research has shown that the inhibition of CHI3L1 diminishes natural adaptive immune responses and reduces cancer growth in vivo in standard and humanized mouse models."

Preclinical • Lung Cancer

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma. (GlobeNewswire) - "Ocean Biomedical, Inc...announced today that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 (CHi3L1) and programmed cell death protein 1 (PD-1), a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a 'master regulator' of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD....The new bispecific patent has been granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer. The newest claims dovetail with and fortify recently issued patents with claims coverage focused on composition of matter of monoclonal antibodies targeting and inhibiting CHi3L1."

Patent • Brain Cancer • Breast Cancer • CNS Tumor • Colon Cancer • Genito-urinary Cancer • Glioblastoma • Kidney Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Prostate Cancer • Rectal Cancer • Skin Cancer • Solid Tumor

Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day (GlobeNewswire) - "In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer....This monoclonal approach has yielded dramatic reduction in mouse lung tumor burden similar to current, cutting-edge monoclonal therapeutics (imaging below), creating the possibility of a new cancer immunotherapy option for patients who have poor response to existing treatments....When the two monospecific antibodies (anti-CHi3L1 and anti-PD1) were administered individually and at the same time an additive effect was seen with 40% of the tumor cells being killed....When the two monospecific antibodies (anti-CHi3L1 and anti-CTLA4) were administered individually and at the same time an additive effect was seen with a 60% decrease in pleural colonies."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer. (GlobeNewswire) - "Ocean Biomedical...announced today that its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing immune system suppression by binding chitinase 3-like-1 (CHi3L1) polypeptides with Ocean Biomedical’s proprietary immunoglobulin antibody. This process has been shown to suppress primary and metastatic tumor growth in multiple animal models and has potential use in multiple forms of visceral cancers."

Patent • Brain Cancer • Breast Cancer • CNS Tumor • Colon Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Glioblastoma • Gynecologic Cancers • Kidney Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Thoracic Cancer

Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody (GlobeNewswire) - "Ocean Biomedical, Inc...announced today that an equity analyst coverage report issued by EF Hutton has increased that firm’s price target by 70%, now targeting $17 per share, up from their initial target of $10 per share....The animal models cited in the studies used mice implanted with human glioblastoma to test the efficacy of Ocean Biomedical’s anti-Chi3L1 therapeutic candidate, and showed tumor reduction of greater than 60% in 2 different study approaches."

Preclinical • Pricing • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody (GlobeNewswire) - "Ocean Biomedical...announced today that its Scientific Co-founder, Jack A. Elias, MD, published new findings in the peer-reviewed journal Cancer Research that detail the mechanisms behind the role of chitinase 3-like-1 (Chi3L1) in the growth of glioblastoma tumors, providing further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth. Results of the research...showed that an independent team...was able to uncover new data on the efficacy of Ocean Biomedical’s anti-Chi3L1 antibody in human glioblastoma implanted mouse models, resulting in clear reduction in glioblastoma tumor growth."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor